Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Recipharm announced the intention to end operations in Ashton-under-Lyne, United Kingdom
Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
Promore Pharma AB (publ) publishes its Year-end report for 2018 at 09.00 CET on 26 February 2019
Strong Launch Continues With More than 550 Patients on Reimbursed Commercial Crysvita® (burosumab) Therapy in the United States at End of 4th Quarter 2018, 80 Percent Increase Versus End of 3rd Quarter
ASIT biotech, a Belgian biopharmaceutical company specialized in the research and development of innovative allergy immunotherapy products, announces its preliminary financial calendar for 2019.
Medtronic plc announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019.
Global healthcare spending is expected to increase dramatically to more than $10 trillion by 2022, driven primarily by an increase in spending on data that will increase value and create a sustainable culture.
The season surrounding Valentine’s Day brings out the love in many people, but for two pharma companies, this year was a year of heartbreak. California-based Aradigm Corporation and New Jersey-based Immune Pharmaceuticals both filed Chapter 11.
NOXXON Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment, published a shareholder letter addressing recent clinical data and outlining its corporate strategy going forward.
Immunicum announced a collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate ilixadencel in combination with Avelumab in multi-indication phase Ib/II study ILIAD.